|

UGN-501 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.1

Indications

  • Urothelial Carcinoma in Situ1
  • Urothelial Carcinoma of the Urinary Bladder1
  • Non-Muscle Invasive Bladder Carcinoma1
  • NMIBC1
  • Urothelial Carcinoma Recurrent1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.